1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Epiomic Epidemiology Series: Thyroid Cancer Forecast in 17 Major Markets 2015-2025

Summary

Black Swan Analysis Epiomic™ Epidemiology Forecast Report on Thyroid Cancer in 17 Major Markets
Thyroid Cancer is a cancer originating from follicular or parafollicular thyroid cells. It is a relatively rare cancer, but the most common of the endocrine system. The main clinical split is between differentiated and undifferentiated tumour types, with the majority being well-differentiated.

This report provides the current incidence population for Thyroid Cancer across 17 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan, Canada, Australia, India, Mexico, Turkey, South Africa, Saudi Arabia, Argentina and Russia) split by gender and 5-year age cohort. Along with the current incidence, the report provides an overview of the stages, locations and histopathology of Thyroid Cancer tumours. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms of Thyroid Cancer have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Thyroid Cancer include:

-Familial Adenomatous Polyposis
-Acromegaly
-Diabetes
-Multiple endocrine neoplasia syndromes
o Sipple syndrome

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

-Able to quantify patient populations in global Thyroid Cancer’s market to target the development of future products, pricing strategies and launch plans.
-Gain further insight into the incidence of the subdivided types of Thyroid Cancer and identify patient segments with high potential.
-Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
-Provide a level of understanding on the impact from specific co-morbid conditions on Thyroid Cancer’s incident population.
-Examination of the incidence of the different causative gene mutations for Thyroid Cancer.
-Identify sub-populations within Thyroid Cancer which require treatment.
-Gain an understanding of the specific markets that have the largest number of Thyroid Cancer patients.

Table Of Contents

Epiomic Epidemiology Series: Thyroid Cancer Forecast in 17 Major Markets 2015-2025
Table of Contents
-List of Tables and Figures
-Introduction
-Cause of the Disease
-Risk Factors and Prevention
-Diagnosis of the Disease
-Variation by Geography/Ethnicity
-Disease Prognosis and Clinical Course
-Key Co-morbid Conditions/ Features Associated with the Disease
-Methodology for Quantification of Patient Numbers
o Additional data available on request
-Top-Line Thyroid Cancer Incidence
-Types of Thyroid Cancer
o Papillary Thyroid Cancer Gene Mutations
-Thyroid Cancer by Stage
o Staging of Thyroid Cancer by Histological Type
-Abbreviations used in the Report
-Other Black Swan Analysis Publications
-Black Swan Analysis Online Patient-Based Databases
-Patient-Based Offering
-Online Pricing Data and Platforms
-References
-Appendix


List of Tables
1. AJCC Tumour Classification for PTC and FTC in over 45 year old patients
2. AJCC Tumour Classification for PTC and FTC in under 45 year old patients
3. AJCC Tumour Classification for MTC
4. AJCC Tumour Classification for ATC
5. Incidence of Thyroid Cancer, total (000s)
6. Incidence of Thyroid Cancer, males (000s)
7. Incidence of Thyroid Cancer, females (000s)
8. Histopathological type in Thyroid Cancer patients, total (000s)
9. Solitary versus Multifocal type in Thyroid Cancer patients, total (000s)
10. BRAF mutations in PTC patients, total (000s)
11. RET/PTC3 gene rearrangement in PTC patients, total (000s)
12. Stage at diagnosis for Thyroid Cancer patients, total (000s)
13. AJCC Staging in PTC patients, total (000s)
14. AJCC Staging in FTC patients, total (000s)
15. AJCC Staging in MTC patients, total (000s)
16. Abbreviations and Acronyms used in the report
17. USA Incidence of Thyroid Cancer by 5-yr age cohort, males (000s)
18. USA Incidence of Thyroid Cancer by 5-yr age cohort, females (000s)
19. France Incidence of Thyroid Cancer by 5-yr age cohort, males (000s)
20. France Incidence of Thyroid Cancer by 5-yr age cohort, females (000s)
21. Germany Incidence of Thyroid Cancer by 5-yr age cohort, males (000s)
22. Germany Incidence of Thyroid Cancer by 5-yr age cohort, females (000s)
23. Italy Incidence of Thyroid Cancer by 5-yr age cohort, males (000s)
24. Italy Incidence of Thyroid Cancer by 5-yr age cohort, females (000s)
25. Spain Incidence of Thyroid Cancer by 5-yr age cohort, males (000s)
26. Spain Incidence of Thyroid Cancer by 5-yr age cohort, females (000s)
27. United Kingdom Incidence of Thyroid Cancer by 5-yr age cohort, males (000s)
28. United Kingdom Incidence of Thyroid Cancer by 5-yr age cohort, females (000s)
29. Brazil Incidence of Thyroid Cancer by 5-yr age cohort, males (000s)
30. Brazil Incidence of Thyroid Cancer by 5-yr age cohort, females (000s)
31. Japan Incidence of Thyroid Cancer by 5-yr age cohort, males (000s)
32. Japan Incidence of Thyroid Cancer by 5-yr age cohort, females (000s)
33. India Incidence of Thyroid Cancer by 5-yr age cohort, males (000s)
34. India Incidence of Thyroid Cancer by 5-yr age cohort, females (000s)
35. Australia Incidence of Thyroid Cancer by 5-yr age cohort, males (000s)
36. Australia Incidence of Thyroid Cancer by 5-yr age cohort, females (000s)
37. Canada Incidence of Thyroid Cancer by 5-yr age cohort, males (000s)
38. Canada Incidence of Thyroid Cancer by 5-yr age cohort, females (000s)
39. Mexico Incidence of Thyroid Cancer by 5-yr age cohort, males (000s)
40. Mexico Incidence of Thyroid Cancer by 5-yr age cohort, females (000s)
41. Turkey Incidence of Thyroid Cancer by 5-yr age cohort, males (000s)
42. Turkey Incidence of Thyroid Cancer by 5-yr age cohort, females (000s)
43. South Africa Incidence of Thyroid Cancer by 5-yr age cohort, males (000s)
44. South Africa Incidence of Thyroid Cancer by 5-yr age cohort, females (000s)
45. Saudi Arabia Incidence of Thyroid Cancer by 5-yr age cohort, males (000s)
46. Saudi Arabia Incidence of Thyroid Cancer by 5-yr age cohort, females (000s)
47. Argentina Incidence of Thyroid Cancer by 5-yr age cohort, males (000s)
48. Argentina Incidence of Thyroid Cancer by 5-yr age cohort, females (000s)
49. Russia Incidence of Thyroid Cancer by 5-yr age cohort, males (000s)
50. Russia Incidence of Thyroid Cancer by 5-yr age cohort, females (000s)
?

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Brain Cancer: Analytical Tool

August 2016 $ 8096

Breast Cancer: Analytical Tool

August 2016 $ 8096

ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.